| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.6 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |